Fig. 3From: The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectivesSchematic representation of immunotherapeutic approaches in T-ALL. Promising approaches based on monoclonal antibodies (mAbs), chimeric antigen receptor (CAR) T-cells and Bispecific T-cell engagers (BTCEs) to increase cure rates in T-ALLBack to article page